Lasofoxifene: Evidence of its therapeutic value in osteoporosis

Gennari, Luigi; Merlotti, Daniela; De Paola, Vincenzo; Nuti, Ranuccio
January 2009
Core Evidence;2009, Vol. 4 Issue 1, p113
Academic Journal
Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, affecting up to 40% postmenopausal women and 15% of men. Among the several therapeutical interventions, hormone replacement therapy (HRT) was traditionally seen as the gold standard for preventing osteoporotic fractures in postmenopausal women, as well as for the management of menopausal symptoms. However HRT, especially if administered long-term, may lead to an increased risk of breast and, when unopposed by progestins, endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective estrogen receptor modulator (SERM). While the former have been associated with suboptimal adherence, the latter was considerably less potent than estrogen and its effect in the prevention of nonvertebral fractures remain uncertain. Aims: The purpose of this article is to review the clinical trials of lasofoxifene, a new SERM for the treatment of postmenopausal osteoporosis. The medical literature was reviewed for appropriate articles containing the terms "lasofoxifene" and SERMs". Evidence review: There are three (phase II or phase III) clinical trials that clearly demonstrate efficacy and safety of this new SERM in the suppression of bone loss and the prevention of vertebral and nonvertebral fractures. Moreover, lasofoxifene treatment also reduced breast cancer risk and the occurrence of vaginal atrophy. Place in therapy: With its increased potency and efficacy on the prevention of nonvertebral fractures lasofoxifene may be an alternative and cost-effective therapy for osteoporosis in postmenopausal women.


Related Articles

  • Exforge® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. Krzesinski, Jean-Marie; Cohen, Eric P. // Core Evidence;2009, Vol. 4 Issue 1, p1 

    Introduction: Hypertension is an important risk factor for cardiovascular disease and its management requires improvement. New treatment strategies are needed. Aims: This review analyses one of these strategies, which is the development of effective and safe combination therapy. Indeed, at least...

  • Luliconazole for the treatment of fungal infections: an evidence-based review. Khanna, Deepshikha; Bharti, Subhash // Core Evidence;2014, Vol. 9, p113 

    Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this...

  • Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton, Katherine A. // Core Evidence;2009, Vol. 4 Issue 1, p191 

    Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the...

  • Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Omar, Ayman I.; Mason, Warren P. // Core Evidence;2009, Vol. 4 Issue 1, p93 

    Introduction: Malignant gliomas are a heterogeneous group of primary central nervous system neoplasms that represent less than 2% of all cancers yet carry a significant burden to society. They are frequently associated with considerable and progressive neurological disability and are ultimately...

  • Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Lieberman, Daniel Z.; Massey, Suena H. // Core Evidence;2009, Vol. 4 Issue 1, p67 

    Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. Aims: The objective of...

  • Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Deibert, Peter; Xander, Carola; Blum, Hubert E.; Becker, Gerhild // Core Evidence;2009, Vol. 4 Issue 1, p247 

    Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new...

  • Agomelatine: The evidence for its place in the treatment of depression. Eser, Daniela; Baghai, Thomas C.; Möller, Hans-Jürgen // Core Evidence;2009, Vol. 4 Issue 1, p171 

    Introduction: Depressive disorders are among the main causes of disability due to disease. In spite of recent progress in the pharmacotherapy of depression, there is still a high nonresponse rate of --30% to the first antidepressant treatment. Furthermore, the latency of several weeks until...

  • Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Reginster, J. -Y.; Bianic, F.; Campbell, R.; Martin, M.; Williams, S. A.; Fitzpatrick, L. A. // Osteoporosis International;Jul2019, Vol. 30 Issue 7, p1465 

    Summary: This network meta-analysis assessed the efficacy of abaloparatide versus other treatment options to reduce the risk of fractures in women with postmenopausal osteoporosis. The analysis indicates that abaloparatide reduces the risk of fractures in women with postmenopausal osteoporosis...

  • Systematic Review: Acupuncture vs Standard Pharmacological Therapy for Migraine Prevention. Zhang, Niushen; Houle, Tim; Hindiyeh, Nada; Aurora, Sheena K. // Headache: The Journal of Head & Face Pain;Feb2020, Vol. 60 Issue 2, p309 

    Background: Standard pharmacological treatment of migraine has many shortcomings. Acupuncture is becoming a more widely used therapy for the prevention and treatment of migraine, but its effectiveness is still in question when compared to the pharmacological treatments even though very few of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics